Skip to content
The Policy VaultThe Policy Vault

Gomekli (mirdametinib) — Medica

Neurofibromatosis type 1 with symptomatic plexiform neurofibromas not amenable to complete resection

Initial criteria

  • Patient is age ≥ 2 years
  • According to the prescriber, patient has or had symptomatic plexiform neurofibromas prior to starting Gomekli
  • The tumor is not amenable to complete resection

Approval duration

1 year